逆转录聚合酶链反应检测激素难治性前列腺癌男性患者前列腺特异性抗原的预后意义

Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.

作者信息

Kantoff P W, Halabi S, Farmer D A, Hayes D F, Vogelzang N A, Small E J

机构信息

Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

出版信息

J Clin Oncol. 2001 Jun 15;19(12):3025-8. doi: 10.1200/JCO.2001.19.12.3025.

DOI:10.1200/JCO.2001.19.12.3025

PMID:11408497

Abstract

PURPOSE

To evaluate the prognostic significance of reverse transcriptase polymerase chain reaction (RT-PCR) detection of prostate-specific antigen (PSA) mRNA in the blood of men with hormone-refractory prostate cancer (HRPC).

PATIENTS AND METHODS

Peripheral blood was obtained from 193 men enrolled on Cancer and Leukemia Group B Study 9480, a prospective randomized comparison of three doses of suramin. RNA was isolated from the samples and assayed for the presence of PSA transcripts by RT-PCR.

RESULTS

RNA could be isolated in 156 (83%) of samples. PSA transcripts as measured by RT-PCR were detectable in 75 (48%) of the 156 patients. The median survival for those patients in whom no transcripts were detectable was 18 months (95% confidence interval [CI], 14 to 22 months) compared with 13 months (95% CI, 11 to 15 months) (P =.004) for those in whom transcripts were detectable. In a multivariate analysis in which other factors predictive of survival were used, RT-PCR for PSA provided independent prognostic information.

CONCLUSION

RT-PCR for PSA predicts survival duration in a population of men with HRPC.

摘要

目的

评估逆转录聚合酶链反应（RT-PCR）检测激素难治性前列腺癌（HRPC）男性患者血液中前列腺特异性抗原（PSA）mRNA的预后意义。

患者与方法

从参与癌症与白血病B组研究9480的193名男性患者中采集外周血，该研究是三种剂量苏拉明的前瞻性随机对照试验。从样本中分离RNA，并用RT-PCR检测PSA转录本的存在情况。

结果

156份样本（83%）可成功分离RNA。在这156例患者中，75例（48%）通过RT-PCR检测到PSA转录本。未检测到转录本的患者中位生存期为18个月（95%置信区间[CI]，14至22个月），而检测到转录本的患者中位生存期为13个月（95%CI，11至15个月）（P = 0.004）。在一项使用其他生存预测因素的多变量分析中，PSA的RT-PCR提供了独立的预后信息。